---
schema_version: "secwatch.filing_event.v1"
accession: "0001746473-26-000088"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2026-05-11T20:07:10+00:00"
generated_at: "2026-05-11T22:38:53.791401+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics Q1 net loss $20M; doses first patient in Phase 1b FORTIFY trial

## Summary
- Q1 net loss $20.0M vs $56.2M prior year; R&D expense $13.6M (down from $43.4M) due to bexotegrast termination and reduced headcount.
- Cash, equivalents and short-term investments $172.4M; expected to fund operations into H2 2028.
- First patient dosed in FORTIFY Phase 1b trial of PLN-101095; interim data expected in 2027.
- Updated Phase 1 data at AACR showed deepening responses: one complete response, two partial responses in checkpoint-refractory tumors.
- Integrin-targeted delivery platform advancing for siRNA delivery to skeletal muscle; preclinical proof-of-concept ongoing.

## SEC filing metadata
- accession: 0001746473-26-000088
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2026-05-11T20:07:10+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000088/0001746473-26-000088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000088/plrx-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001746473-26-000088
- JSON: https://secwatch.observer/filing/0001746473-26-000088.json
- Plain text: https://secwatch.observer/filing/0001746473-26-000088.txt

## Key facts
- Earnings Releases
  PLIANT THERAPEUTICS, INC. reported first quarter ended March 31, 2026 results: net income Net loss was $20.0 million.
  - Period: first quarter ended March 31, 2026
  - Net income: Net loss was $20.0 million
  - Result: reported results
  source text: On May 11, 2026, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000088/0001746473-26-000088-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.